Smartphone app boosts chemo nurse Know-How in small trial
NCT ID NCT06976450
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a mobile app called ChemoNurs, designed to help oncology nurses learn about chemotherapy drugs. Fifty-nine nurses from one hospital in Turkey used the app, and researchers measured changes in their knowledge and attitudes. The goal was to see if a simple smartphone tool could improve how nurses handle chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ChemoNurs mobile application
- What this could lead to
- If effective, this app could become a simple tool to help nurses feel more confident and knowledgeable when giving chemotherapy.
- What could go wrong
- This was a small, single-center study with only 59 nurses. Results may not apply to other hospitals or countries, and the app's long-term impact is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hacettepe University Oncology Hospital
Ankara, Altındağ, 06230, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?